Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.

about

Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.

Item

http://www.wikidata.org/entity/Q49199576

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@en

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@nl

type

Item

label

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@en

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@nl

prefLabel

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@en

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@nl

P1476

Bortezomib overcomes the negat ...... ltiple myeloma: A case report.

@en

P2093

Binbin Wang

http://www.w3.org/2001/XMLSchema#string

Cunbang Wang

http://www.w3.org/2001/XMLSchema#string

Hai Bai

http://www.w3.org/2001/XMLSchema#string

Jinmao Zhou

http://www.w3.org/2001/XMLSchema#string

Shuting Zhang

http://www.w3.org/2001/XMLSchema#string

Tao Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular pathogenesis of multiple myeloma: basic and clinical updates

Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Minor clone provides a reservoir for relapse in multiple myeloma

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

International uniform response criteria for multiple myeloma.

P304

7318-7322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.7151

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29344169

http://www.w3.org/2001/XMLSchema#string

P932

5754884

http://www.w3.org/2001/XMLSchema#string